$XENE
Xenon Pharmaceuticals Inc.

2019 Q3 Form 10-Q Financial Statement

#000156459019040449 Filed on November 05, 2019

View on sec.gov

Income Statement

Concept 2019 Q3 2018 Q3 2018 Q2
Revenue $3.500M $0.00 $0.00
YoY Change -100.0% -100.0%
Cost Of Revenue $0.00 $6.000M
YoY Change -100.0%
Gross Profit $3.500M -$6.000M
YoY Change -158.33%
Gross Profit Margin 100.0%
Selling, General & Admin $2.700M $1.940M $2.180M
YoY Change 39.18% 11.49% 21.11%
% of Gross Profit 77.14%
Research & Development $9.751M $6.248M $5.416M
YoY Change 56.07% -12.79% -11.36%
% of Gross Profit 278.6%
Depreciation & Amortization $100.0K $150.0K $150.0K
YoY Change -33.33% -11.76% -6.25%
% of Gross Profit 2.86%
Operating Expenses $9.751M $14.18M $7.594M
YoY Change -31.22% 59.16% -3.99%
Operating Profit -$6.251M -$14.18M -$7.594M
YoY Change -55.91% 64.02% -3.79%
Interest Expense $363.0K $678.0K $200.0K
YoY Change -46.46% -24.67% -60.78%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$8.866M -$14.39M -$7.810M
YoY Change -38.39% 85.93% 5.83%
Income Tax $5.000K -$8.000K -$8.000K
% Of Pretax Income
Net Earnings -$8.871M -$14.38M -$7.801M
YoY Change -38.32% 85.78% 5.7%
Net Earnings / Revenue -253.46%
Basic Earnings Per Share -$0.63
Diluted Earnings Per Share -$343.9K -$0.63 -$342.0K
COMMON SHARES
Basic Shares Outstanding 20.31M 14.31M
Diluted Shares Outstanding 20.31M 14.31M

Balance Sheet

Concept 2019 Q3 2018 Q3 2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $94.60M $127.1M $63.30M
YoY Change -25.57% 190.18% 22.44%
Cash & Equivalents $37.67M $87.96M $47.44M
Short-Term Investments $56.90M $39.20M $15.80M
Other Short-Term Assets $1.700M $2.200M $900.0K
YoY Change -22.73% 100.0% 28.57%
Inventory
Prepaid Expenses
Receivables $209.0K $200.0K $200.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $96.48M $129.5M $64.40M
YoY Change -25.5% 187.78% 22.43%
LONG-TERM ASSETS
Property, Plant & Equipment $1.212M $1.000M $1.100M
YoY Change 21.2% -16.67% -15.38%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $200.0K $0.00
YoY Change -100.0%
Total Long-Term Assets $2.426M $1.000M $1.000M
YoY Change 142.6% -28.57% -37.5%
TOTAL ASSETS
Total Short-Term Assets $96.48M $129.5M $64.40M
Total Long-Term Assets $2.426M $1.000M $1.000M
Total Assets $98.90M $130.5M $65.40M
YoY Change -24.21% 181.25% 20.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.400M $1.000M $900.0K
YoY Change 40.0% -67.74% -76.32%
Accrued Expenses $6.600M $3.400M $2.200M
YoY Change 94.12%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $3.616M $0.00
YoY Change
Total Short-Term Liabilities $11.70M $4.400M $3.100M
YoY Change 165.84% 41.94% -18.42%
LONG-TERM LIABILITIES
Long-Term Debt $11.79M $14.89M $11.72M
YoY Change -20.82%
Other Long-Term Liabilities $900.0K
YoY Change
Total Long-Term Liabilities $11.79M $14.89M $11.72M
YoY Change -20.82%
TOTAL LIABILITIES
Total Short-Term Liabilities $11.70M $4.400M $3.100M
Total Long-Term Liabilities $11.79M $14.89M $11.72M
Total Liabilities $24.34M $19.30M $14.80M
YoY Change 26.11% 531.13% 289.47%
SHAREHOLDERS EQUITY
Retained Earnings -$238.3M
YoY Change
Common Stock $306.1M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $74.56M $111.2M $50.62M
YoY Change
Total Liabilities & Shareholders Equity $98.90M $130.5M $65.40M
YoY Change -24.21% 181.5% 20.66%

Cashflow Statement

Concept 2019 Q3 2018 Q3 2018 Q2
OPERATING ACTIVITIES
Net Income -$8.871M -$14.38M -$7.801M
YoY Change -38.32% 85.78% 5.7%
Depreciation, Depletion And Amortization $100.0K $150.0K $150.0K
YoY Change -33.33% -11.76% -6.25%
Cash From Operating Activities -$7.200M -$13.72M -$5.540M
YoY Change -47.52% 58.98% -18.53%
INVESTING ACTIVITIES
Capital Expenditures -$50.00K -$20.00K -$140.0K
YoY Change 150.0% 100.0% 40.0%
Acquisitions
YoY Change
Other Investing Activities $7.920M -$23.33M $2.080M
YoY Change -133.95% 29062.5% -77.97%
Cash From Investing Activities $7.880M -$23.35M $1.940M
YoY Change -133.75% 25844.44% -79.21%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 20.00K 77.43M 34.01M
YoY Change -99.97% 340000.0%
NET CHANGE
Cash From Operating Activities -7.200M -13.72M -5.540M
Cash From Investing Activities 7.880M -23.35M 1.940M
Cash From Financing Activities 20.00K 77.43M 34.01M
Net Change In Cash 700.0K 40.36M 30.41M
YoY Change -98.27% -562.84% 1097.24%
FREE CASH FLOW
Cash From Operating Activities -$7.200M -$13.72M -$5.540M
Capital Expenditures -$50.00K -$20.00K -$140.0K
Free Cash Flow -$7.150M -$13.70M -$5.400M
YoY Change -47.81% 58.93% -19.4%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-207885000
CY2018Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-990000
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-8535000
CY2018Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12762000
us-gaap Preferred Stock Shares Authorized Unlimited
PreferredStockSharesAuthorizedUnlimited
Unlimited
us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
us-gaap Investment Income Interest
InvestmentIncomeInterest
558000
us-gaap Interest Expense
InterestExpense
1037000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-23433000
CY2019Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y6M
CY2018Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
148000
CY2018Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
325000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17232000
CY2018Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-8000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1916000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-14383000
CY2018Q3 xene Net Income Loss Available To Preferred Stockholders Basic
NetIncomeLossAvailableToPreferredStockholdersBasic
1621000
us-gaap Interest Expense
InterestExpense
1086000
us-gaap Operating Income Loss
OperatingIncomeLoss
-31221000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
185000
CY2018Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-14391000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-30206000
us-gaap Operating Income Loss
OperatingIncomeLoss
-29586000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13000
CY2018Q3 us-gaap Interest Expense
InterestExpense
678000
us-gaap Net Income Loss
NetIncomeLoss
-30219000
CY2019Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-80000
CY2019Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-8866000
us-gaap Operating Expenses
OperatingExpenses
29586000
CY2019Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
5000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-8871000
CY2019Q3 xene Net Income Loss Available To Preferred Stockholders Basic
NetIncomeLossAvailableToPreferredStockholdersBasic
336000
CY2018Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2018 us-gaap Preferred Stock Shares Authorized Unlimited
PreferredStockSharesAuthorizedUnlimited
Unlimited
CY2018 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2018Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
CY2018Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
CY2019Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37671000
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2019Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
158000
CY2019Q3 us-gaap Liabilities Current
LiabilitiesCurrent
11697000
CY2018Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4119000
CY2019Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
857000
CY2019Q3 us-gaap Liabilities
Liabilities
24340000
CY2019Q3 us-gaap Preferred Stock Value
PreferredStockValue
7732000
CY2019Q3 us-gaap Common Stock Value
CommonStockValue
266425000
CY2019Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
39676000
CY2019Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-238279000
CY2019Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-990000
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
74564000
CY2019Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
98904000
CY2019Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1016000
CY2019Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1016000
CY2019Q3 us-gaap Common Stock No Par Value
CommonStockNoParValue
CY2019Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25868594
CY2019Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25868594
CY2019Q3 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
3500000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9751000
CY2019Q3 us-gaap Assets Current
AssetsCurrent
96478000
CY2018Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
122428000
CY2018Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
25750721
CY2018Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
1016000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
3500000
CY2019Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1036000
CY2019Q3 us-gaap Assets
Assets
98904000
CY2019Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1212000
CY2019Q3 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
56932000
CY2018Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
1016000
CY2019Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
209000
CY2018Q4 us-gaap Liabilities
Liabilities
19133000
CY2018Q4 us-gaap Preferred Stock Value
PreferredStockValue
7732000
CY2018Q4 us-gaap Common Stock Value
CommonStockValue
265923000
CY2018Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
991000
CY2019Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1666000
CY2018Q4 us-gaap Assets
Assets
122428000
CY2019Q3 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
7923000
CY2018Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
4119000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
103295000
CY2018Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
25750721
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6248000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27093000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2700000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-25943000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-4000
us-gaap Net Income Loss
NetIncomeLoss
-25939000
xene Net Income Loss Available To Preferred Stockholders Basic
NetIncomeLossAvailableToPreferredStockholdersBasic
2506000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.34
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17472403
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-276000
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20306298
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25773732
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-29073000
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.33
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.63
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.13
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-3755000
CY2019Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0375
CY2019Q3 xene Accrued Consulting And Contracted Research Current
AccruedConsultingAndContractedResearchCurrent
4013000
CY2019Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
302000
CY2019Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
145000
CY2019Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2663788
CY2019Q3 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
1371000
CY2019Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2092000
CY2018Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1728000
CY2018Q4 xene Accrued Consulting And Contracted Research Current
AccruedConsultingAndContractedResearchCurrent
1404000
CY2018Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
237000
CY2018Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
85000
CY2018Q4 us-gaap Accounts Payable Trade Current
AccountsPayableTradeCurrent
665000
CY2018Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
15014000
dei Security12b Title
Security12bTitle
Common Shares, without par value
dei Trading Symbol
TradingSymbol
XENE
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Transition Report
DocumentTransitionReport
false
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
67754000
CY2018Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
51552000
CY2018Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
151000
CY2018Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1875000
CY2018Q4 us-gaap Assets Current
AssetsCurrent
121332000
CY2019Q3 us-gaap Deferred Tax Assets Liabilities Net Noncurrent
DeferredTaxAssetsLiabilitiesNetNoncurrent
178000
CY2018Q4 us-gaap Deferred Tax Assets Liabilities Net Noncurrent
DeferredTaxAssetsLiabilitiesNetNoncurrent
105000
CY2019Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
3616000
CY2019Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
11786000
CY2018Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
38515000
CY2019Q3 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1938000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7628000
CY2018Q3 xene Buy Out Of Future Milestones And Royalties Expense
BuyOutOfFutureMilestonesAndRoyaltiesExpense
6000000
CY2019Q3 us-gaap Interest Expense
InterestExpense
363000
us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
4398000
xene Net Income Loss Available To Preferred Stockholders Basic
NetIncomeLossAvailableToPreferredStockholdersBasic
1146000
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25793482
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
35934000
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
28498000
CY2018Q2 us-gaap Net Income Loss
NetIncomeLoss
-7801000
CY2018Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
28957000
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
657000
CY2018Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
63000
CY2018Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
247000
CY2018Q2 us-gaap Stockholders Equity
StockholdersEquity
50621000
CY2018Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
73885000
CY2018Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
662000
CY2018Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
80000
CY2018Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
291000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
111156000
CY2019Q1 us-gaap Cumulative Effect On Retained Earnings Net Of Tax1
CumulativeEffectOnRetainedEarningsNetOfTax1
-175000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-11341000
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
476000
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
58000
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
92313000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-10007000
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
470000
CY2019Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
11000
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
82787000
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
630000
CY2019Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
18000
us-gaap Profit Loss
ProfitLoss
-30219000
us-gaap Profit Loss
ProfitLoss
-25939000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
283000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
445000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
388000
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
156000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-73000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-94000
us-gaap Share Based Compensation
ShareBasedCompensation
1567000
us-gaap Share Based Compensation
ShareBasedCompensation
2050000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
161000
us-gaap Foreign Currency Transaction Gain Loss Unrealized
ForeignCurrencyTransactionGainLossUnrealized
-269000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
54000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-349000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-208000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1239000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
3694000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
919000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24367000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-27482000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
645000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
337000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
76064000
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
50130000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
70684000
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
34036000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6025000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-16431000
us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
8453000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
102842000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
87000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
262000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
87000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
111557000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
222000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-168000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-30083000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
67476000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
67754000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
20486000
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
37671000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
87962000
us-gaap Interest Paid Net
InterestPaidNet
702000
us-gaap Interest Paid Net
InterestPaidNet
338000
us-gaap Interest Income Deposits With Financial Institutions
InterestIncomeDepositsWithFinancialInstitutions
1938000
us-gaap Interest Income Deposits With Financial Institutions
InterestIncomeDepositsWithFinancialInstitutions
518000
us-gaap Operating Lease Payments
OperatingLeasePayments
469000
us-gaap Operating Lease Payments
OperatingLeasePayments
465000
xene Fair Value Of Stock Options Exercised On Cashless Basis
FairValueOfStockOptionsExercisedOnCashlessBasis
354000
xene Fair Value Of Stock Options Exercised On Cashless Basis
FairValueOfStockOptionsExercisedOnCashlessBasis
1112000
us-gaap Stock Issued1
StockIssued1
21825000
us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
9893000
us-gaap Basis Of Accounting
BasisOfAccounting
<div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:4.54%;white-space:nowrap"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td> <td valign="top"> <p style="text-align:justify;margin-top:18pt;margin-bottom:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Basis of presentation:</p></td></tr></table></div> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These consolidated financial statements are presented in U.S. dollars.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has one wholly-owned subsidiary as of September&#160;30, 2019, Xenon Pharmaceuticals USA Inc., which was incorporated in Delaware on December 2, 2016.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These unaudited interim consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany transactions and balances have been eliminated on consolidation. Certain prior year amounts have been reclassified to conform to the current year presentation.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying unaudited interim consolidated financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (&#8220;SEC&#8221;) for interim financial information. Accordingly, these consolidated financial statements do not include all of the information and footnotes required for complete consolidated financial statements and should be read in conjunction with the audited consolidated financial statements and notes for the year ended December&#160;31, 2018 and included in the Company&#8217;s 2018 Annual Report on Form 10-K filed with the SEC and with the securities commissions in British Columbia, Alberta and Ontario on March 6, 2019.</p> <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These unaudited interim consolidated financial statements reflect all adjustments, consisting of normal recurring adjustments, which, in the opinion of management, are necessary for a fair presentation of results for the interim periods presented. The results of operations for the three and nine month periods ended September&#160;30, 2019 and 2018 are not necessarily indicative of results that can be expected for a full year. These unaudited interim consolidated financial statements follow the same significant accounting policies as those described in the notes to the audited consolidated financial statements of the Company included in the Company&#8217;s 2018 Annual Report on Form 10-K for the year ended December&#160;31, 2018, with the exception of the policy described in note 3 below. </p>
CY2019Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
109000
us-gaap Operating Lease Cost
OperatingLeaseCost
328000
CY2019Q3 us-gaap Variable Lease Cost
VariableLeaseCost
136000
us-gaap Variable Lease Cost
VariableLeaseCost
404000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
155000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
621000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
587000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
140000
CY2019Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1503000
CY2019Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
56000
CY2019Q3 xene Future Lease Incentives Reasonably Certain Of Use
FutureLeaseIncentivesReasonablyCertainOfUse
432000
CY2019Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1015000
CY2019Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
5167000
CY2019Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
6200000
CY2019Q3 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
4133000
CY2019Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
15500000
CY2018Q1 us-gaap Gain Loss On Contract Termination
GainLossOnContractTermination
4398000
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1180175
CY2019Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
148948
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0279
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.69
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.75
CY2018Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M7D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y10D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y4M20D
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.24
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
8.75
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
6.22
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.70
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.76
CY2019Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y14D
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
43096
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
3651919
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1846826
CY2018Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2831985
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
12000
CY2018Q3 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
119129
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
42593
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2682263
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1471329
xene Stock Options Exercised For Number Of Common Shares For Cash
StockOptionsExercisedForNumberOfCommonSharesForCash
23625
xene Stock Options Exercised For Number Of Common Shares For Cash
StockOptionsExercisedForNumberOfCommonSharesForCash
41507
xene Common Stock Issued For Cashless Exercise
CommonStockIssuedForCashlessExercise
94248
xene Common Stock Issued For Cashless Exercise
CommonStockIssuedForCashlessExercise
103189
xene Cashless Exercise Of Stock Options
CashlessExerciseOfStockOptions
151186
xene Cashless Exercise Of Stock Options
CashlessExerciseOfStockOptions
196341
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0176
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0281
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0177
CY2019Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.69

Files In Submission

Name View Source Status
0001564590-19-040449-index-headers.html Edgar Link pending
0001564590-19-040449-index.html Edgar Link pending
0001564590-19-040449.txt Edgar Link pending
0001564590-19-040449-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
xene-10q_20190930.htm Edgar Link pending
xene-20190930.xml Edgar Link completed
xene-20190930.xsd Edgar Link pending
xene-20190930_cal.xml Edgar Link unprocessable
xene-20190930_def.xml Edgar Link unprocessable
xene-20190930_lab.xml Edgar Link unprocessable
xene-20190930_pre.xml Edgar Link unprocessable
xene-ex311_6.htm Edgar Link pending
xene-ex312_8.htm Edgar Link pending
xene-ex321_9.htm Edgar Link pending
xene-ex322_7.htm Edgar Link pending